-
- 1
- 2
- 3
- 4
- 5
Scan to visit
High Purity of GSK-2118436 Dabrafenib Mesylate 1195768-06-9
| Payment Type: | T/T,L/C |
|---|---|
| Min. Order: | 1 Gram |
- Mr. Tommy
Basic Info
Model No.: 1195768-06-9
Brand: CONBOTTPHARM
Additional Info
Packaging: As quantity
Productivity: As requiry
Transportation: Air
Place of Origin: CHINA
Supply Ability: Commercial
Certificate: DOCUMENT SUPPORT
Payment Type: T/T,L/C
Product Description
Competitive High Purity of GSK-2118436 Dabrafenib Mesylate Inhibitor
Dabrafenib is a kinase inhibitor with anticancer activity. we can make good purity (99% single impurity< 0.1%) we have rich experience in making dabrafenib mesylate Cas 1195768-06-9 Dabrafenib Mesylate manufacturers and suppliers in China.
Thera. Category: Anti- cancer
Cas No.: 1195768-06-9
Synonym: Dabrafenib Mesylate(GSK-2118436B);Dabrafenib Mesylate;GSK 2118436 Mesylate;GSK 2118436B;GSK2118436 Mesylate;GSK-2118436 Mesylate;Dabrafenib Mesylate (API);GSK 2118436 methanesulfonate salt
Molecular Formula:C24H24F3N5O5S3
Molecular Weight: 615.6680696
Assay: ≥97.%
Packing: Export worthy packing
Material Safety Data Sheet: Available on request
Usage: Dabrafenib, also known as GSK2118436, is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. On May 29, 2013, FDA approved this drug.
Related Intermediates :
1. CAS 630-22-8,2,2,2-Trimethylthioacetamide
2. CAS 914223-43-1,3-AMINO-2-FLUOROBENZOIC ACID
Product Categories : Inhibitors > BRAF Inhibitors
